radiolabelled rhTIMP-2; iodine-123; in vivo biodistribution; SPECT; tumour imaging
Abstract :
[en] Matrix metalloproteinases (MMPs) are enzymes involved in the turnover of the extracellular matrix. Their overexpression in tumours may provide a target for diagnostic imaging by using labelled MMP inhibitors. MMPs are inhibited by endogenous tissue inhibitors of metalloproteinases (TIMPs). The enhanced production of MT1-MMP, located on the surface of cells within or in the direct vicinity of the tumour, and the high affinity interaction between TIMP-2 and MT1-MMP suggested that TIMP-2 could be a potential agent for non-invasive monitoring of cancer MMP levels, diagnosis of primary and secondary tumours and tumour response to MMP inhibitor therapy. There is also evidence that I-125-rhTIMP-2 internalizes, which is an important feature for its possible use as a radiotherapeuticum if labelled with I-131. Labelling of rhTIMP-2 was performed using the iodogen method resulting in a radiochemical yield of 51.1 +/- 11.8% (n = 5) and a radiochemical purity of > 98%. The trichloroacetic acid (TCA) precipitability of I-123 rhTIMP-2 was 95.2%. SDS-PAGE confirmed the correct size (21 kDa) of the purified I-123 rhTIMP-2 without degradation. HPLC showed one radioactive peak with a retention time corresponding to the nonlabelled rhTIMP-2. In vivo biodistribution showed no long-term accumulation in organs and the possibility to accumulate in the tumour. These results show the potential of I-123 rhTIMP-2 as tumour-imaging agent. Copyright (c) 2005 John Wiley
Egeblad M, Werb Z. Nat Rev Cancer 2002; 2: 161-174.
McCawley LJ, Matrisian LM. Mol Med Today 2000; 6: 149-156.
Maquoi E, Peyrollier K, Noël A, Foidart JM, Frankenne F. Biochem J 2003; 373: 19-24.
Seiki M. Acta Pathol Microbiol Immunol Scand 1999; 107: 137-143.
Toth M, Bernardo MM, Gervasi DC, Soloway PD, Wang Z, Bigg HF, Overall CM, DeClerck YA, Tschesche H, Cher ML, Brown S, Mobashery S, Fridman R. J Biol Chem 2000; 275(52): 41415-41423.
Sato T, Iwai M, Sakai T, Sato H, Seiki M, Mori Y, Ito A. Br J Cancer 1999; 80(8): 1137-1143.
Butler GS, Butler MJ, Atkinson SJ, Will H, Tamura T, van Westrum SS, Crabbe T, Clements J, d'Ortho MP, Murphy G. J Biol Chem 1998; 273(2): 871-880.
Bernardo MM, Fridman R. Biochem J 2003; 374: 739-745.
Uekita T, Itoh Y, Yana I, Ohno H, Seiki M. J Cell Biol 2001; 155: 1345-1356.
De Clerck YA, Yean TD, Chan D, Shimada H, Langley KE. Cancer Res 1991; 51: 2151-2157.
Noël A, Santavicca M, Stoll I, L'Hoir C, Staub A, Murphy G, Rio MC, Basset P. J Biol Chem 1995; 270(22): 866-872.
Haisma HJ, Hilgers J, Zurawski Jr VR. J Nucl Med 1986; 27: 1890-1895.
Hajitou A, Baramova EN, Bajou K, Noe V, Bruyneel E, Marcel M, Collette J, Foidart JM, Calberg-Bacq CM. Oncogene 1998; 17(16): 2059-2071.
Goffin F, Munaut C, Frankenne F, d'Hauterive SP, Béliard A, Fridman V, Nervo P, Colige A, Foidart JM. Biol Reprod 2003; 69(3): 976-984.
Lahorte C, Dumont F, Slegers G, Van de Wiele C, Dierckx RA. Nucl Med Commun 1999; 20(10): 948-949.
Hajitou A, Sounni NE, Devy L, Grignet-Debrus C, Lewalle JM, Li H, Deroanne CF, Lu H, Colige A, Nusgens BV, Frankenne F, Maron A, Yeh P, Perricaudet M, Chang Y, Soria C, Calberg-Bacq CM, Foidart JM, Noel A. Cancer Res 2001; 61(8): 3450-3457.